Does VTE increase risk of subsequent MACE (cardiac events ie MI). National Data Bank excluded pts with past CV events. 2X risk of future CVE post VTE. Strange as risks are a bit different #ACRbest #ACR19 @RheumNow abst196 https://t.co/XoSkow7AAQ

Efficacy and Safety of Upadacitinib in a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2/3 Clinical Study of Patients With Active AS • Onset of response to upadacitinib 15 mg QD tx was rapid • AEs similar between upadacitinib and placebo #ACR19 @RheumNow

Abstr#2273: higher placental transfer antiTNFs=ADA,IFX,GOL. Less transfer=CTZ,ETN. No ⬆️ in infxns in offspring, even with 3rd tri exposure. Potential trend for ⬆️ in serious infxns (>/=1 hosp adm 1st yr of life) with high placental transfer antiTNFs, not sig. #ACR2019 @RheumNow https://t.co/qEIl9lxlv1

Secukinumab: a human IgG1κ monoclonal antibody that binds to IL-17A ASAS40: a composite measure including patient global, pain, function, and inflammation In patients with nr-AxSpA, secukinumab improved ASAS40 through week 52, compared to placebo Dr. Deodhar #ACR19 @RheumNow https://t.co/yLwt47w2wr

MYTH: Tocilizumab should be reserved for GCA patients whom prednisone has failed #PearlsAndMyths Dr. John Stone #ACR19 @RheumNow https://t.co/tVrC5XP0ot

Interesting withdrawal study of tofacitinib in children with JIA showed that drug was better than placebo at preventing disease flares. #pedirheum #ACR19 @RheumNow https://t.co/lHWNJGmmtF

NEW ANCA Associated Vasculitis Guidelines - discussed at #ACR19 1. Rituxan > cytoxan 2. Reduced steroid regimen! 3. Rec against PLEX 4. Rec FOR scheduled RTX over ANCA+B cell guided 5. MTX for limited dx Well done everyone - very reasonable and evidence based! @RheumNow https://t.co/oX6qEJDQON

NEW Draft Guidelines for EGPA presented at #ACR19 @RheumNow 1. TTE and FFS to guide tx 2. GC plus cytoxan or rituxan for active/severe dx 3. Imuran/MMF/MTX for maintenance after severe dx 4. Mepo for non-severe over csDMARDs Larger role for RTX than expected, overall reasonable https://t.co/MEb10n5Mzd

Video from @gensler_MD on AS and nr-axSpA studies presented at #ACR19 @rheumnow https://t.co/fcn9zCxouU via @YouTube

• Highlights of AS, Psoriatic Arthritis Studies: Dr. Lianne Gensler - YouTube

Pregnancy outcome in the DESIR cohort (SpA cohort) #ACR19 @RheumNow https://t.co/PcwR6rrMRw

The bit I particularly like out of this: you get *at least* another 10% from going back for more slices from your temporal artery biopsy. Please, sir, may I have some more (slices)? Reggio Emilia #ACR19 ABST2648 @RheumNow

The more we know, the more we learn we struggle to predict GCA flares. Model based on three large GCA cohorts (total n=778) could pick some factors (headaches, limb claudication, aortitis, CRP) but couldn't discriminate well. Other variables important? #ACR19 ABST2650 @RheumNow

In case we needed more reassurance: ANCA positivity on IF without a MPO or PR3 rarely leads to ANCA-associated vasculitis. Maybe if the pathology report had that info attached, it would help reassure our generalist colleagues? @ShaareZedekMed #ACR19 ABST2642 @RheumNow

MGUS is really common in the general population. Therefore, it’s going to be really common in our rheumatic patient population #acr19 https://t.co/9HIWvDm20n

Here’s the risk stratification for MGUS #ACR19 @rheumnow 5T064 https://t.co/fKeJu8n5DI